The natural history of growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS)

Molecular Genetics and Metabolism

Volumn 117, Issue 4, 2016, Pages 438-446

  Parini, Rossella ^a   Jones, Simon A ^b   Harmatz, Paul R ^c   Giugliani, Roberto ^d   Mendelsohn, Nancy J ^e,f  

^a SAN GERARDO HOSPITAL   (Italy)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Head circumference; Height; Lysosomal storage disease; Mucopolysaccharidosis type II; Puberty; Weight

Indexed keywords

ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; COGNITIVE DEFECT; DISEASE SEVERITY; GROUPS BY AGE; GROWTH ACCELERATION; GROWTH RATE; HEAD CIRCUMFERENCE; HUMAN; HUNTER SYNDROME; MACROCEPHALY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT STATURE; ADOLESCENT; CLINICAL TRIAL; FEMALE; GROWTH; LONGITUDINAL STUDY; MORPHOMETRY; MUCOPOLYSACCHARIDOSIS II; MULTICENTER STUDY; PHENOTYPE; PRESCHOOL CHILD; QUESTIONNAIRE; REGISTER; SELF REPORT; YOUNG ADULT;

ADOLESCENT; AGE OF ONSET; BODY WEIGHTS AND MEASURES; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH; HUMANS; LONGITUDINAL STUDIES; MALE; MUCOPOLYSACCHARIDOSIS II; PHENOTYPE; REGISTRIES; SELF REPORT; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84960194506     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2016.01.009     Document Type: Article

References (54)

1. [1] Neufeld, E.F., Muenzer, J., The mucopolysaccharidoses. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., (eds.) The Metabolic and Molecular Bases of Inherited Disease, 2001, McGraw-Hill, New York, 3421–3452.
2. [2] Lin, H.Y., Lin, S.P., Chuang, C.K., Niu, D.M., Chen, M.R., Tsai, F.J., Chao, M.C., Chiu, P.C., Lin, S.J., Tsai, L.P., Hwu, W.L., Lin, J.L., Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am. J Med Genet A 149A (2009), 960–964.
3. [3] Poorthuis, B.J., Wevers, R.A., Kleijer, W.J., Groener, J.E., de Jong, J.G., van Weely, S., Niezen-Koning, K.E., Diggelen, O.P. van, The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 105 (1999), 151–156.
4. [4] Baehner, F., Schmiedeskamp, C., Krummenauer, F., Miebach, E., Bajbouj, M., Whybra, C., Kohlschutter, A., Kampmann, C., Beck, M., Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. 28 (2005), 1011–1017.
5. [5] Marucha, J., Jurecka, A., Syczewska, M., Rozdzynska-Swiatkowska, A., Tylki-Szymanska, A., Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr. 101 (2012), e183–e188.
6. [6] Pinto, L.L., Schwartz, I.V., Puga, A.C., Vieira, T.A., Munoz, M.V., Giugliani, R., Prospective study of 11 Brazilian patients with mucopolysaccharidosis II. J. Pediatr. 82 (2006), 273–278.
7. [7] Young, I.D., Harper, P.S., The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev. Med. Child Neurol. 25 (1983), 481–489.
8. [8] Young, I.D., Harper, P.S., Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch. Dis. Child. 57 (1982), 828–836.
9. [9] Schwartz, I.V., Ribeiro, M.G., Mota, J.G., Toralles, M.B., Correia, P., Horovitz, D., Santos, E.S., Monlleo, I.L., Fett-Conte, A.C., Sobrinho, R.P., Norato, D.Y., Paula, A.C., Kim, C.A., Duarte, A.R., Boy, R., Valadares, E., De Michelena, M., Mabe, P., Martinhago, C.D., Pina-Neto, J.M., Kok, F., Leistner-Segal, S., Burin, M.G., Giugliani, R., A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr. 96 (2007), 63–70.
10. [10] Jones, S.A., Almassy, Z., Beck, M., Burt, K., Clarke, J.T., Giugliani, R., Hendriksz, C., Kroepfl, T., Lavery, L., Lin, S.P., Malm, G., Ramaswami, U., Tincheva, R., Wraith, J.E., Mortality and cause of death in mucopolysaccharidosis type II — a historical review based on data from the Hunter Outcome Survey (HOS). J. Inherit. Metab. Dis. 32 (2009), 534–543.
11. [11] Rozdzynska, A., Tylki-Szymanska, A., Jurecka, A., Cieslik, J., Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr. 100 (2011), 456–460.
12. [12] Rozdzynska-Swiatkowska, A., Jurecka, A., Cieslik, J., Tylki-Szymanska, A., Growth patterns in children with mucopolysaccharidosis I and II. World J. Pediatr., 2014.
13. [13] Patel, P., Suzuki, Y., Maeda, M., Yasuda, E., Shimada, T., Orii, K.E., Orii, T., Tomatsu, S., Growth charts for patients with Hunter syndrome. Mol. Genet. Metab. Rep. 1 (2014), 5–18.
14. [14] Wraith, J.E., Beck, M., Giugliani, R., Clarke, J., Martin, R., Muenzer, J., Initial report from the Hunter Outcome Survey. Genetics in Medicine 10 (2008), 508–516.
15. [15] Schulze-Frenking, G., Jones, S.A., Roberts, J., Beck, M., Wraith, J.E., Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J. Inherit. Metab. Dis. 34 (2011), 203–208.
16. [16] Muenzer, J., Beck, M., Giugliani, R., Suzuki, Y., Tylki-Szymanska, A., Valayannopoulos, V., Vellodi, A., Wraith, J.E., Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genetics in Medicine 13 (2011), 102–109.
17. [17] Jones, S.A., Parini, R., Harmatz, P., Giugliani, R., Fang, J., Mendelsohn, N.J., The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol. Genet. Metab. 109 (2013), 41–48.
18. [18] Khosla, T., Lowe, C.R., Indices of obesity derived from body weight and height. Br. J. Prev. Soc. Med. 21 (1967), 122–128.
19. [19] Kuczmarski, R.J., Ogden, C.L., Grummer-Strawn, L.M., Flegal, K.M., Guo, S.S., Wei, R., Mei, Z., Curtin, L.R., Roche, A.F., Johnson, C.L., CDC growth charts: United States. Adv. Data, 2000, 1–27.
20. [20] Nellhaus, G., Head circumference from birth to eighteen years. Practical composite international and interracial graphs. Pediatrics 41 (1968), 106–114.
21. [21] Tanner, J.M., Whitehouse, R.H., Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch. Dis. Child. 51 (1976), 170–179.
22. [22] Quartel, A., Hendriksz, C.J., Parini, R., Graham, S., Lin, P., Harmatz, P., Growth charts for individuals with mucopolysaccharidosis VI (Maroteaux–Lamy Syndrome). JIMD Rep. 18 (2015), 1–11.
23. [23] Harmatz, P., Mengel, K.E., Giugliani, R., Valayannopoulos, V., Lin, S.P., Parini, R., Guffon, N., Burton, B.K., Hendriksz, C.J., Mitchell, J., Martins, A., Jones, S., Guelbert, N., Vellodi, A., Hollak, C., Slasor, P., Decker, C., The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol. Genet. Metab. 109 (2013), 54–61.
24. [24] Heppner, J.M., Zaucke, F., Clarke, L.A., Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in mucopolysaccharidosis I. Mol. Genet. Metab. 114 (2015), 146–155.
25. [25] L.A. Clarke, Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator Rheumatology (Oxford) 50 Suppl 5 (2011) v13–18.
26. [26] Nuttall, J.D., Brumfield, L.K., Fazzalari, N.L., Hopwood, J.J., Byers, S., Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif. Tissue Int. 65 (1999), 47–52.
27. [27] Wilson, S., Hashamiyan, S., Clarke, L., Saftig, P., Mort, J., Dejica, V.M., Bromme, D., Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am. J. Pathol. 175 (2009), 2053–2062.
28. [28] Metcalf, J.A., Zhang, Y., Hilton, M.J., Long, F., Ponder, K.P., Mechanism of shortened bones in mucopolysaccharidosis VII. Mol. Genet. Metab. 97 (2009), 202–211.
29. [29] Smith, L.J., Baldo, G., Wu, S., Liu, Y., Whyte, M.P., Giugliani, R., Elliott, D.M., Haskins, M.E., Ponder, K.P., Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII. Mol. Genet. Metab. 107 (2012), 153–160.
30. [30] Simonaro, C.M., D'Angelo, M., He, X., Eliyahu, E., Shtraizent, N., Haskins, M.E., Schuchman, E.H., Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 172 (2008), 112–122.
31. [31] Hendriksz, C.J., Harmatz, P., Beck, M., Jones, S., Wood, T., Lachman, R., Gravance, C.G., Orii, T., Tomatsu, S., Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol. Genet. Metab. 110 (2013), 54–64.
32. [32] Swiedler, S.J., Beck, M., Bajbouj, M., Giugliani, R., Schwartz, I., Harmatz, P., Wraith, J.E., Roberts, J., Ketteridge, D., Hopwood, J.J., Guffon, N., Sa Miranda, M.C., Teles, E.L., Berger, K.·.I., Piscia-Nichols, C., Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am. J. Med. Genet. A 134A (2005), 144–150.
33. [33] Dung, V·.C., Tomatsu, S., Montano, A.M., Gottesman, G., Bober, M.B., Mackenzie, W., Maeda, M., Mitchell, G.A., Suzuki, Y., Orii, T., Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol. Genet. Metab. 110 (2013), 129–138.
34. [34] Scarpa, M., Almassy, Z., Beck, M., Bodamer, O., Bruce, I.A., De Meirleir, L., Guffon, N., Guillen-Navarro, E., Hensman, P., Jones, S., Kamin, W., Kampmann, C., Lampe, C., Lavery, C.A., Teles, E.L., Link, B., Lund, A.M., Malm, G., Pitz, S., Rothera, M., Stewart, C., Tylki-Szymanska, A., van der Ploeg, A., Walker, R., Zeman, J., Wraith, J.E., Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet. J. Rare. Dis., 6, 2011, 72.
35. [35] de Ruijter, J., Broere, L., Mulder, M.F., van der Ploeg, A.T., Rubio-Gozalbo, M.E., Wortmann, S.B., Visser, G., Wijburg, F.A., Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease). J. Inherit. Metab. Dis. 37 (2014), 447–454.
36. [36] Zhang, H., Wood, T., Young, S.P., Millington, D.S., A straightforward, quantitative ultra-performance liquid chromatography–tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses. Mol. Genet. Metab. 114 (2015), 123–128.
37. [37] Chuang, C.K., Lin, H.Y., Wang, T.J., Tsai, C.C., Liu, H.L., Lin, S.P., A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet. J. Rare. Dis., 9, 2014, 135.
38. [38] Osago, H., Shibata, T., Hara, N., Kuwata, S., Kono, M., Uchio, Y., Tsuchiya, M., Quantitative analysis of glycosaminoglycans, chondroitin/dermatan sulfate, hyaluronic acid, heparan sulfate, and keratan sulfate by liquid chromatography–electrospray ionization-tandem mass spectrometry. Anal. Biochem. 467 (2014), 62–74.
39. [39] Gardner, C.J., Robinson, N., Meadows, T., Wynn, R., Will, A., Mercer, J., Church, H.J., Tylee, K., Wraith, J.E., Clayton, P.E., Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). J. Inherit. Metab. Dis. 34 (2011), 489–497.
40. [40] Tanner, J.M., Foetus Into Man. Physical Growth From Conception to Maturity. 1989, Castlemead Publications.
41. [41] Dimeglio, A., Growth in pediatric orthopaedics. J. Pediatr. Orthop. 21 (2001), 549–555.
42. [42] Vellodi, A., Young, E.P., Cooper, A., Wraith, J.E., Winchester, B., Meaney, C., Ramaswami, U., Will, A., Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch. Dis. Child. 76 (1997), 92–99.
43. [43] J. Karlberg, On the construction of the infancy–childhood–puberty growth standard, Acta Paediatr. Scand. Suppl 356 (1989) 26–37.
44. [44] Potegal, M., Yund, B., Rudser, K., Ahmed, A., Delaney, K., Nestrasil, I., Whitley, C.B., Shapiro, E.G., Mucopolysaccharidosis type IIIA presents as a variant of Kluver–Bucy syndrome. J. Clin. Exp. Neuropsychol. 35 (2013), 608–616.
45. [45] Simonaro, C.M., Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation. J. Pediatr. Rehabil. Med. 3 (2010), 85–88.
46. [46] Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., Capeau, J., Feve, B., Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 (2006), 4–12.
47. [47] Gabrielli, O., Polonara, G., Regnicolo, L., Petroni, V., Scarabino, T., Coppa, G.V., Salvolini, U., Correlation between cerebral MRI abnormalities and mental retardation in patients with mucopolysaccharidoses. Am. J. Med. Genet. A 125A (2004), 224–231.
48. [48] Vedolin, L., Schwartz, I.V., Komlos, M., Schuch, A., Puga, A.C., Pinto, L.L., Pires, A.P., Giugliani, R., Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. AJNR Am. J. Neuroradiol. 28 (2007), 1029–1033.
49. [49] Fan, Z., Styner, M., Muenzer, J., Poe, M., Escolar, M., Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II. AJNR Am. J. Neuroradiol. 31 (2010), 1319–1323.
50. [50] Holt, J.B., Poe, M.D., Escolar, M.L., Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics 127 (2011), e1258–e1265.
51. [51] Parini, R., Rigoldi, M., Tedesco, L., Boffi, L., Brambilla, A., Bertoletti, S., Boncimino, A., Del Longo, A., De Lorenzo, P., Gaini, R., Gallone, D., Gasperini, S., Giussani, C., Grimaldi, M., Grioni, D., Meregalli, P., Messinesi, G., Nichelli, F., Romagnoli, M., Russo, P., Sganzerla, E., Valsecchi, G., Biondi, A., Enzymatic replacement therapy for Hunter disease: up to 9 years experience with 17 patients. Mol. Genet. Metab. Rep. 3 (2015), 65–74.
52. [52] Williams, C.A., Dagli, A., Battaglia, A., Genetic disorders associated with macrocephaly. Am. J. Med. Genet. A 146A (2008), 2023–2037.
53. [53] Link, B., de Camargo Pinto, L.L., Giugliani, R., Wraith, J.E., Guffon, N., Eich, E., Beck, M., Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop. Rev. (Pavia), 2, 2010, e16.
54. [54] Tanner, J.M., Davies, P.S., Clinical longitudinal standards for height and height velocity for North American children. J. Pediatr. 107 (1985), 317–329.